A federal advisory panel voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is advisory only. The FDA has given no clear statement on whether it will follow the advice. The move came after weeks of open hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could shift how the agency handles a part of the wellness market that is growing very fast. Market observers are watching to see if the FDA follows through on the vote. A spokesperson for the regulator offered no clear schedule for a reaction. Supporters argue the change would open up access to substances some say help. Skeptics warn that looser rules could open the door to misuse across a barely regulated market. The Thursday vote only sets up a possible shift, and the final say rests with the regulator.